TUG
Sight from ... Sound
Therapeutic
Ultrasound for
Glaucoma





Glaucoma
More than 76 million cases in 2020 Estimated 112 million cases by 2040
28% increase of primary open-angle glaucoma in the US per decade to approximately 7.32 million by 2050
50% of persons with early stage glaucoma are unaware that they have the disease
$5.5 billion = Estimated annual US Glaucoma health care budget
#1 Cause of Irreversible Blindness Worldwide








Breakthrough Therapy
One Time, 10 Minute Treatment
No Pressure Spikes, Well Tolerated
Replace or Supplement Medications
Treated eyes show an increased thickness of the Retinal Nerve Fiber Layer
4 of 5


Delivering an Effective Solution
Comparable results to SLT for treatment with patients currently on medications.
80% of treatment naïve patients had ≥ 20% IOP reduction from baseline at 12 month follow-up.
Use for most glaucoma variants
Minimal equipment required
Non-invasive / Ab externo






Meet Our Team
EyeSonix's team strives to extend "sighted life" worldwide by making available a simple and highly effective glaucoma treatment, breaking the paradigm of present day glaucoma care.


DONALD SCHWARTZ, OD, MD
President and Founder


ERIC SCHULTZ, MS
CEO, CTO and Co-Founder


OMID KHODAI, OD, MS
Clinical & Regulatory
SHARON BAKALASH, MD, PhD
Board Member
DALE HEUER, MD
Medical Advisor


VINCENT M. PATELLA, OD
Medical Advisor


BARRY SEIBEL, MD
Medical Advisor
JOHN SAMPLES, MD
Medical Advisor
ALAN ROBIN, MD
Clinical Advisor
JAGDEEP KAKADIA, MD, PhD
Medical Advisor
DARYL MICHALIK, MBA
Business Development
TOSIN SMITH, MD
Medical Advisor
STEPHANIE KAPLAN, MBA
Operations & Quality
DAVID RICHARDSON, MD
Medical Advisor
RAMESH SHAH, MD
Medical Advisor
Contact Us
If you're interested in hearing more about the technology, have a business proposal, or are interested in making a purchase, we'd love to hear from you.